SCHEMBL18558338

SCHEMBL18558338

CC(C)CN/C(=N/C(=O)c1cccc(C#N)c1)Nc1cc(-c2cc(F)cc(F)c2)n[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 1/20 0.38
VNN1 O95497 2/20 0.35
MAPK1 P28482 2/20 0.35
MCHR1 Q99705 1/20 0.35
GSK3B P49841 2/20 0.34
ALDH1A1 P00352 1/20 0.33
GRM5 P41594 1/20 0.33
CDC7 O00311 1/20 0.33
DAPK3 O43293 1/20 0.33
ROCK2 O75116 1/20 0.33
PAK4 O96013 1/20 0.33
CDK2 P24941 1/20 0.33
FLT3 P36888 1/20 0.33
CSNK1A1 P48729 1/20 0.33
CDK8 P49336 1/20 0.33
CLK2 P49760 1/20 0.33
CDK7 P50613 1/20 0.33
CDK9 P50750 1/20 0.33
PRKX P51817 1/20 0.33
CDK5 Q00535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558245 0.93 VNN1 (0.39) GPR139VNN1MAPK1MCHR1GSK3B
SCHEMBL18557779 0.89 GPR139 (0.37) GPR139GSK3BROCK2DYRK1AALPL
SCHEMBL18558204 0.89 VNN1 (0.40) GPR139VNN1MCHR1GSK3BGRM5
SCHEMBL18558081 0.89 MAPK1 (0.37) GPR139VNN1MAPK1GSK3BGRM5
SCHEMBL18558451 0.88 MAPK1 (0.36) GPR139VNN1MAPK1GRM5
SCHEMBL18558452 0.87 GPR139 (0.35) GPR139VNN1MAPK1GSK3BGRM5
SCHEMBL18558455 0.85 VNN1 (0.35) VNN1MAPK1GRM5
SCHEMBL18558413 0.85 HDAC3 (0.39) MAPK1ALDH1A1ALPL
SCHEMBL18558468 0.84 ALPL (0.38) MAPK1ALDH1A1DYRK1AALPL
SCHEMBL18558415 0.83 ALPL (0.41) MAPK1GSK3BALDH1A1DYRK1AALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME GPR139 4205/4885VNN1 2342/4885MAPK1 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.